Shares of clinical-stage biotech firm Sangamo Therapeutics Inc. fell nearly 3% in Monday's after-hours trading following ...

Q4 2024 Earnings Call Transcript March 17, 2025 Sangamo Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

In the assessment of 12-month price targets, analysts unveil insights for Sangamo Therapeutics, presenting an average target ...

Sangamo Therapeutics Inc (SGMO) reports significant progress in its Fabry disease program and neurology therapies, while ...

Truist Financial analyst Nicole Germino maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report) today. The company’s shares ...

Reports Q4 revenue $7.6M, consensus $11.7M. “I am pleased with Sangamo’s (SGMO) pipeline progress since the start of 2024. We advanced our two ...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and fourth quarter and full year 2024 financial results. “I am pleased with ...

Sangamo Therapeutics Inc. (SGMO) ...

Sangamo Therapeutics, with a market capitalization of $211.78 million, reported its earnings for Q4 2024, posting an EPS of -0.11, slightly missing the forecast of -0.10. Revenue came in at 7.55 ...

Alexander Macrae; President, Chief Executive Officer, Director; Sangamo Therapeutics Inc Nathalie Dubois- Stringfellow; Senior Vice President, Chief Development Officer; Sangamo Therapeutics Inc Good ...

RICHMOND, Calif. (AP) — RICHMOND, Calif. (AP) — Sangamo Therapeutics Inc. (SGMO) on Monday reported a loss of $23.4 million in its fourth quarter. On a per-share basis, the Richmond ...